RxDoctor Payments Data

Noah Starkey, MD

Internal Medicine · Enfield, CTNPI 1376648345

Payments from drug & device makers

$18,634in general payments, 2019–2025

Across 1,380 payments — averaging $13.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$3K
  • GSK$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$863
  • plus $7K from 47 others

What the payments were for

  • Food & beverage$18,41799%
  • Education$2171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$18,634 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$29,844
Medicare patients
148
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol101$95,154
JardianceEmpagliflozin56$75,064
MounjaroTirzepatide46$56,579
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$54,083
TrulicityDulaglutide34$49,123
OzempicSemaglutide42$47,209
EliquisApixaban41$42,034
Xigduo XrDapaglifloz Propaned/Metformin23$29,432
RybelsusSemaglutide19$29,356
Synjardy XrEmpagliflozin/Metformin Hcl25$27,757
Repatha SureclickEvolocumab18$24,009
JanuviaSitagliptin Phosphate19$23,079
Janumet XrSitagliptin Phos/Metformin Hcl13$20,359
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$18,514
EdarbyclorAzilsartan Med/Chlorthalidone29$18,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,152$105,70280 claims
Boehringer IngelheimJardiance, Synjardy Xr$863$102,82181 claims
AstraZenecaFarxiga$1,145$95,154101 claims
Novo NordiskOzempic, Rybelsus$2,821$76,56661 claims
GSKTrelegy Ellipta, Anoro Ellipta$2,367$72,59757 claims
MerckJanuvia, Janumet Xr$214$43,43732 claims
PfizerEliquis$589$42,03441 claims
Johnson & JohnsonXarelto, Invokamet$381$27,15224 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$549$18,27729 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$285$6,88613 claims
AbbVieSynthroid$3,237$3,16644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Enfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →